KH 176

Drug Profile

KH 176

Alternative Names: KH176

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Khondrion
  • Class Antiparkinsonians; Benzopyrans; Piperidines; Small molecules
  • Mechanism of Action Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - MELAS syndrome; Leigh disease; Mitochondrial disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mitochondrial disorders
  • Preclinical Parkinson's disease

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Mitochondrial disorders(In volunteers) in Belgium (PO)
  • 01 Dec 2017 Chemical structure information added
  • 08 Nov 2017 Khondrion has patent protection for KH 176 in USA, Europe and Hong Kong
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top